EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 6522 participants.
Also called NCT04509674
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 6,522 participants
- Registry
-
NCT04509674 -
2019-001037-13
-
- Other papers using this trial's data
- Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial
- Empagliflozin after Acute Myocardial Infarction
- Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Brazil, Bulgaria, Canada, China, Denmark, France, Germany, Hungary, India, Israel, Japan, Netherlands, Poland, Romania, Russia, Serbia, South Korea, Spain, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT04509674. Randomized; quadruple masking; primary purpose treatment. Start 2020-12-16 (actual); primary completion 2023-11-05 (actual). Results posted on 2025-01-07.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)
- Condition
- Myocardial Infarction
- Intervention (Drug)
- Empagliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Boehringer Ingelheim
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct04509674- Content hash
5095dba731800a7827c8a40824c700817c5fa56a869f9620948624416077891b